Novartis receives Japanese approval for Zolgensma for spinal muscular atrophy Medical Dialogues Bureau22 March 2020 11:45 AM ISTZolgensma is a one-time gene therapy designed to address the genetic root cause of the disease by replacing the function of the missing or nonworking...
Pfizer, Novartis lead USD 2 billion spending spree on gene therapy production Medical Dialogues Bureau28 Nov 2019 9:00 AM ISTNew Delhi: Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018,...
Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Another delay in USD 2.1 million gene therapy Zolgensma data reporting, Novartis admits mistake Medical Dialogues Bureau3 Nov 2019 9:45 AM ISTThe USFDA on Wednesday placed a partial hold on a Novartis trial of the $2.1 million-per-patient gene therapy, Zolgensma after the company informed...
SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns Medical Dialogues Bureau31 Oct 2019 9:45 AM ISTNovartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
Cigna new plan to cover expensive gene therapies including Novartis Zolgensma, Luxturna Medical Dialogues Bureau8 Sept 2019 9:00 AM ISTThe first two gene therapies to be included in Cigna Corp's program are blindness therapy, Luxturna, and the most expensive drug in the world...
Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales Medical Dialogues Bureau7 Sept 2019 9:15 AM ISTRoche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for...
Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA Medical Dialogues Bureau8 Aug 2019 9:15 AM ISTThe FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval of...
Novartis gets USFDA nod for over Rs 13 crore gene therapy Zolgensma Farhat Nasim25 May 2019 10:00 AM ISTThe Food and Drug Administration on Friday approved the treatment, called Zolgensma, for all children under age 2 who are confirmed by a genetic test...
